FolioLanternBeta
EIKNEikon Therapeutics, Inc. · Insider ownership research

Eikon Therapeutics, Inc. insiders: what they own and what they did with it

None of it through sales. No officer or director reported an open-market sale in this period.

Updated Oct 13, 2026 from SEC filings · covers Oct 14, 2025 to Oct 13, 2026
1
buyer among officers and directors (1 trade), past 12 months
0 of 9
officers and directors sold shares, past 12 months
Latest filing: Filed Feb 10 for a conversion on Feb 6. Roger Perlmutter converted 285K shares between classes. Filing
SEC ownership filings: 28 filed in the 12 months to Oct 13, 2026; 28 on record since Feb 4, 2026 · See the evidence

What stands out

Kenneth Frazier bought 111K shares for $2.0M, first on Feb 4, 2026. These are the first purchases by current officers or directors in the filings on record.Purchase, Feb 4, 2026

No officer or director sold shares in this period. 9 are left out

i
Left out: Roger Perlmutter, Alfred Bowie Jr., Benjamin Thorner, Michael Klobuchar, Kenneth Frazier, Roy Baynes, David Meline, Robert Huffines and Ma Francisco (share of stake is being verified).
Disclosed company stock is not an insider's whole wealth.

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Feb 4, 2026Kenneth Frazier bought 111K shares ($2.0M).
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Kenneth Frazier
Director
111,111$18.00n/an/aFeb 4, 2026Feb 6, 2026

Outside holders, reported separately

Column Group IV GP, LP, Lux Venture Partners V, LLC and Foresite Capital Management IV, LLC reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Eikon Therapeutics, Inc. CEO selling stock?

No. Roger Perlmutter reported no open-market sales in the past 12 months.

Are any Eikon Therapeutics, Inc. insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold0 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan

Outside holder, reported separately: Column Group IV GP, LP (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Lux Venture Partners V, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Foresite Capital Management IV, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 9 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Roger Perlmutter
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Roger Perlmutter are complete.
Chief Executive Officer and Director, Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Roger Perlmutter

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Roger Perlmutter are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
869,981$9.85Feb 3, 2032$1.5M
1,608,481$9.85Apr 1, 2035$2.7M
268,176$14.88Mar 1, 2036$0

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Alfred Bowie Jr.
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Alfred Bowie Jr. are complete.
Chief Financial Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Alfred Bowie Jr.

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alfred Bowie Jr. are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
55,698$1.94Jul 28, 2031$536K
33,521$9.85Jan 12, 2033$57K
26,147$9.85Mar 10, 2034$45K
63,691$9.85Apr 1, 2035$109K
67,044$14.88Mar 1, 2036$0

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Benjamin Thorner
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Benjamin Thorner are complete.
General Counsel and Chief Business Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Benjamin Thorner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Benjamin Thorner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
127,383$9.85Jan 20, 2032$218K
26,817$9.85Jan 12, 2033$46K
30,169$9.85Mar 10, 2034$52K
83,804$9.85Apr 1, 2035$143K
67,044$14.88Mar 1, 2036$0

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Michael Klobuchar
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Michael Klobuchar are complete.
Chief Operating Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Michael Klobuchar

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Klobuchar are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
134,087$9.85May 2, 2035$229K
40,226$9.85May 2, 2035$69K
87,157$14.88Mar 1, 2036$0

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Kenneth Frazier
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kenneth Frazier are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Kenneth Frazier

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kenneth Frazier are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
67,043$9.85Aug 7, 2032$115K
16,760$9.85Jan 16, 2034$29K
25,873$14.88Mar 1, 2036$0

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Roy Baynes
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Roy Baynes are complete.
Chief Medical Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Roy Baynes

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Roy Baynes are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
134,087$9.85May 30, 2032$229K
32,181$9.85Mar 10, 2034$55K
101,906$9.85Apr 1, 2035$174K
134,088$14.88Mar 1, 2036$0

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

David Meline
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Meline are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for David Meline

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Meline are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
67,043$11.12Nov 20, 2035$29K

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Robert Huffines
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Robert Huffines are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Robert Huffines

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Huffines are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
67,043$9.85Nov 16, 2033$115K
25,873$14.88Mar 1, 2036$0

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Ma Francisco
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ma Francisco are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Ma Francisco

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ma Francisco are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
85,937$8.96Jun 4, 2036$223K

Estimate: options held × ($11.56 − strike price), using the most recent insider trade price on Form 4 (Sep 3, 2026), not a market close.

Holdings and share of stake for Eikon Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

Known gaps and uncertainty9 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Eikon Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology28 filings on record, 28 filed in the 12-month period, and how we read them

All 28 Forms 3, 4 and 5 on record for Eikon Therapeutics, Inc. (SEC CIK 1861123), filed from Feb 4, 2026 to Sep 8, 2026; 28 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (1)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
Leon ChenNo balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.